FASEB J. Cell Migration Consortium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DONNELLAN, R.
Right arrow Articles by CHETTY, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DONNELLAN, R.
Right arrow Articles by CHETTY, R.
(The FASEB Journal. 1999;13:773-780.)
© 1999 FASEB


Reviews

Cyclin E in human cancers

RORY DONNELLAN1 and RUNJAN CHETTY

Department of Pathology, University of Natal Medical School, Durban, South Africa

1Correspondence: Department of Pathology, University of Natal Medical School, Private Bag 7, Congella 4013, Durban, Kwazulu-Natal, South Africa. E-mail: donnellanr{at}med.und.ac.za

Regulators of the cell cycle such as cyclin E play an important part in neoplasia. The cyclin E protein forms a partnership with a specific protein kinase. This complex phosphorylates key substrates to initiate DNA synthesis. Cyclin-dependent kinase inhibitors (CKIs) are able to suppress the activity of cyclin E. Various substances (including proteins produced by oncogenic viruses) affect cyclin E directly or indirectly through an interaction with CKIs. These interactions are important in elucidating the mechanisms of neoplasia. They may also provide prognostic information in a wide range of common cancers. Cyclin E may even be a target for treatment of cancers in the future.—Donnellan, R., Chetty, R. Cyclin E in human cancers.


Key Words: cell cycle • cyclins • cyclin-dependent kinase • CKIs




This article has been cited by other articles:


Home page
J. Virol.Home page
X. Zheng, X.-M. Rao, J. G. Gomez-Gutierrez, H. Hao, K. M. McMasters, and H. S. Zhou
Adenovirus E1B55K Region Is Required To Enhance Cyclin E Expression for Efficient Viral DNA Replication
J. Virol., April 1, 2008; 82(7): 3415 - 3427.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
A N A Milne, R Carvalho, M Jansen, E K Kranenbarg, C J H van de Velde, F M Morsink, A R Musler, M A J Weterman, and G J A Offerhaus
Cyclin E low molecular weight isoforms occur commonly in early-onset gastric cancer and independently predict survival
J. Clin. Pathol., March 1, 2008; 61(3): 311 - 316.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
G. Deep, N. H. Oberlies, D. J. Kroll, and R. Agarwal
Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells
Carcinogenesis, July 1, 2007; 28(7): 1533 - 1542.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. D. McEvoy, U. Kossatz, N. Malek, and J. D. Singer
Constitutive Turnover of Cyclin E by Cul3 Maintains Quiescence
Mol. Cell. Biol., May 15, 2007; 27(10): 3651 - 3666.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Spruck, D. Sun, H. Fiegl, C. Marth, E. Mueller-Holzner, G. Goebel, M. Widschwendter, and S. I. Reed
Detection of low molecular weight derivatives of cyclin e1 is a function of cyclin e1 protein levels in breast cancer.
Cancer Res., July 15, 2006; 66(14): 7355 - 7360.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. P. Jackson, S. I. Reed, and S. B. Haase
Distinct mechanisms control the stability of the related s-phase cyclins clb5 and clb6.
Mol. Cell. Biol., March 1, 2006; 26(6): 2456 - 2466.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
P. Potemski, E. Pluciennik, A. K. Bednarek, R. Kusinska, D. Jesionek-Kupnicka, G. Pasz-Walczak, C. Watala, and R. Kordek
Cyclin E Expression in Operable Breast Cancer Quantified Using Real-Time RT-PCR: A Comparative Study with Immunostaining
Jpn. J. Clin. Oncol., March 1, 2006; 36(3): 142 - 149.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Mani and E. P. Gelmann
The Ubiquitin-Proteasome Pathway and Its Role in Cancer
J. Clin. Oncol., July 20, 2005; 23(21): 4776 - 4789.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
S. I. Reed
Deregulation of Cyclin E in Cancer
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 53 - 56.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. E. Bani-Hani, N. M. Almasri, Y. S. Khader, F. M. Sheyab, and H. N. Karam
Combined Evaluation of Expressions of Cyclin E and p53 Proteins as Prognostic Factors for Patients with Gastric Cancer
Clin. Cancer Res., February 15, 2005; 11(4): 1447 - 1453.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Schoonjans, L. Dubuquoy, J. Mebis, E. Fayard, O. Wendling, C. Haby, K. Geboes, and J. Auwerx
Liver receptor homolog 1 contributes to intestinal tumor formation through effects on cell cycle and inflammation
PNAS, February 8, 2005; 102(6): 2058 - 2062.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
Z. Yu, J. Lin, Y. Xiao, J. Han, X. Zhang, H. Jia, Y. Tang, and Y. Li
Induction of Cell-Cycle Arrest by all-trans Retinoic Acid in Mouse Embryonic Palatal Mesenchymal (MEPM) Cells
Toxicol. Sci., February 1, 2005; 83(2): 349 - 354.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H.-P. Lin, S. K. Kulp, P.-H. Tseng, Y.-T. Yang, C.-C. Yang, C.-S. Chen, and C.-S. Chen
Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms
Mol. Cancer Ther., December 1, 2004; 3(12): 1671 - 1680.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
B. L. Schneider and M. Kulesz-Martin
Destructive cycles: the role of genomic instability and adaptation in carcinogenesis
Carcinogenesis, November 1, 2004; 25(11): 2033 - 2044.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
L. Richard-Parpaillon, R. A. Cosgrove, C. Devine, A. E. Vernon, and A. Philpott
G1/S phase cyclin-dependent kinase overexpression perturbs early development and delays tissue-specific differentiation in Xenopus
Development, June 1, 2004; 131(11): 2577 - 2586.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. M. Harwell, B. B. Mull, D. C. Porter, and K. Keyomarsi
Activation of Cyclin-dependent Kinase 2 by Full Length and Low Molecular Weight Forms of Cyclin E in Breast Cancer Cells
J. Biol. Chem., March 26, 2004; 279(13): 12695 - 12705.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pathol.Home page
A A Khan, P D Abel, K S Chaudhary, Z Gulzar, G W H Stamp, and E-N Lalani
Inverse correlation between high level expression of cyclin E and proliferation index in transitional cell carcinoma of the bladder
Mol. Pathol., December 1, 2003; 56(6): 353 - 361.
[Abstract] [Full Text] [PDF]


Home page
Biophys. JHome page
Z. Qu, W. R. MacLellan, and J. N. Weiss
Dynamics of the Cell Cycle: Checkpoints, Sizers, and Timers
Biophys. J., December 1, 2003; 85(6): 3600 - 3611.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
Z. Qu, J. N. Weiss, and W. R. MacLellan
Regulation of the mammalian cell cycle: a model of the G1-to-S transition
Am J Physiol Cell Physiol, February 1, 2003; 284(2): C349 - C364.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
L. Wiebusch, J. Asmar, R. Uecker, and C. Hagemeier
Human cytomegalovirus immediate-early over protein 2 (IE2)-mediated activation of cyclin E is cell-cycle-independent and forces S-phase entry in IE2-arrested cells
J. Gen. Virol., January 1, 2003; 84(1): 51 - 60.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Geisen and T. Moroy
The Oncogenic Activity of Cyclin E Is Not Confined to Cdk2 Activation Alone but Relies on Several Other, Distinct Functions of the Protein
J. Biol. Chem., October 11, 2002; 277(42): 39909 - 39918.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. H. Spruck, H. Strohmaier, O. Sangfelt, H. M. Muller, M. Hubalek, E. Muller-Holzner, C. Marth, M. Widschwendter, and S. I. Reed
hCDC4 Gene Mutations in Endometrial Cancer
Cancer Res., August 15, 2002; 62(16): 4535 - 4539.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Gao and D. R. Richardson
The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression
Blood, August 1, 2001; 98(3): 842 - 850.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
D. C. Porter and K. Keyomarsi
Novel splice variants of cyclin E with altered substrate specificity
Nucleic Acids Res., December 1, 2000; 28(23): e101 - e101.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Ravanko, K. Järvinen, A. Paasinen-Sohns, and E. Hölttä
Loss of p27Kip1 from Cyclin E/Cyclin-dependent Kinase (CDK) 2 but not from Cyclin D1/CDK4 Complexes in Cells Transformed by Polyamine Biosynthetic Enzymes
Cancer Res., September 1, 2000; 60(18): 5244 - 5253.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
R. M. Harwell, D. C. Porter, C. Danes, and K. Keyomarsi
Processing of Cyclin E Differs between Normal and Tumor Breast Cells
Cancer Res., January 1, 2000; 60(2): 481 - 489.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by The Federation of American Societies for Experimental Biology.